Thus, we conducted a 2-year post-marketing study in patients with HER2-negative inoperable or recurrent breast cancer in a clinical setting in Japan to assess the effectiveness (OS) and safety of eribulin including in patients using eribulin as a first- or second-line treatment. This evidence concerns the gene ERBB2 and breast carcinoma.